In­tel­lia to cut work­force by 27%, plans com­mer­cial­iza­tion of first CRISPR ther­a­py in 2027

In­tel­lia Ther­a­peu­tics is the lat­est CRISPR com­pa­ny re­sort­ing to lay­offs as in­vestors in­creas­ing­ly turn away from gene edit­ing.
The Cam­bridge, MA-based com­pa­ny an­nounced Thurs­day that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER